Clinical Trial Search

Primary: AUCinf: Area Under Plasma Concentration-time Curve From 0 to Infinity in Fasted Condition — 180.4; 195.2; 4486; 4332 hour*nanogram/millilitre

Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml

Primary: Change in the Cardiff Wound Impact Schedule-Physical Symptoms of Daily Living (CWIS-PSDL) Scale Score From Baseline to the Week 6 Visit — 54.3; 54.0; 71.2; 56.3 score on…

Primary: Change in Patient Health Questionnaire-9 Item Scale (PHQ-9) Over 3 Months Post-discharge — 0.09; -0.50 score on a scale — p=0.61

Primary: Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score — -3.26; -2.26 score on a scale — p=0.1146

Primary: Number of Participants at Each Global Rank Endpoint Based Upon Their Most-severe Outcome — 12; 17; 3; 7 Participants — p=0.14

Primary: Change in Clinical Pain as Assessed by the Numeric Rating Scale (NRS) for Pain — -24.07; -1.08 score on a scale

Primary: Number of Participants With PSA Remission Assessed Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria — 29; 16 Participants

Primary: Alcohol Quantity — 27.37; 25.95; 32.02; 32.15 number of drinks on peak occasion — p=.461

Primary: Number of Participants With Ocular Treatment Emergent Adverse Events — 16 Participants

Primary: Rates of Severe Adverse Events (SAEs) Across Study Arms — 0; 0; 0 Participants

Primary: Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68 — 92.6; 91.9…

Primary: Fatigue Index From the Isokinetic Fatigue Test — 61.7; 46.7; 57.28; 55.90 Percent decline — p=<0.05

Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal

Primary: Number of RBD Episodes in One Month (Per Patient RBD Log) — 37.5; 35.0; 23.5; 25.5 episodes — p=0.03